Nanovibronix (NASDAQ:FEED – Get Free Report) and Biosig Technologies (NASDAQ:STEX – Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, institutional ownership, dividends and analyst recommendations.
Insider and Institutional Ownership
16.4% of Nanovibronix shares are held by institutional investors. Comparatively, 7.2% of Biosig Technologies shares are held by institutional investors. 1.4% of Nanovibronix shares are held by company insiders. Comparatively, 52.7% of Biosig Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility and Risk
Nanovibronix has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500. Comparatively, Biosig Technologies has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nanovibronix | $2.69 million | 1.15 | -$3.70 million | ($41.74) | -0.07 |
| Biosig Technologies | $40,000.00 | 9,615.90 | -$10.33 million | ($1.35) | -1.79 |
Nanovibronix has higher revenue and earnings than Biosig Technologies. Biosig Technologies is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings for Nanovibronix and Biosig Technologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nanovibronix | 1 | 0 | 0 | 0 | 1.00 |
| Biosig Technologies | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares Nanovibronix and Biosig Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nanovibronix | -275.12% | -24.78% | -19.24% |
| Biosig Technologies | N/A | N/A | -64.96% |
Summary
Nanovibronix beats Biosig Technologies on 6 of the 11 factors compared between the two stocks.
About Nanovibronix
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
About Biosig Technologies
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company’s proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.
